Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
暂无分享,去创建一个
R. Levy | M. Czuczman | A. Ho | P. Mclaughlin | F. Cabanillas | F. Cabanillas | V. Jain | C. White | J. Lister | M. Williams | B. Link | I. Bence-Bruckler | A. Grillo-López | M. E. Williams | M. Heyman | K. Wey | D. Shen | B. Dallaire | R. Levy | A. Grillo‐López | I. Bence‐Bruckler | Michael E. Williams
[1] D. Maloney,et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .
[2] W. Hiddemann,et al. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] D. Czerwinski,et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma , 1994 .
[4] T. Tedder,et al. CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.
[5] J. Gribben,et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow , 1994 .
[6] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[7] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[8] T. Maughan,et al. Adverse reactions to Campath-1H monoclonal antibody , 1993, The Lancet.
[9] J. Armitage,et al. Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[10] I. Bernstein,et al. Monoclonal antibody-based therapies of leukemia and lymphoma. , 1992, Blood.
[11] E. Everett,et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia , 1992, American journal of hematology.
[12] S. Gillies,et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.
[13] J. Ghrayeb,et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Brown,et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.
[15] R. R. Robinson,et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.
[16] F. Appelbaum,et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.
[17] T. Lister,et al. Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Carlo,et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. , 1984, Blood.
[19] R. Dillman,et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Pinkus,et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.
[21] S. Sallan,et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. , 1981, Blood.
[22] D. Kufe,et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.
[23] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .